Galsulfase
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Galsulfase: From Mucopolysaccharidosis to Ptosis-Strabismus-Ectopic Pupils Syndrome
One-Sentence Summary
Galsulfase is a recombinant enzyme replacement therapy originally used to treat mucopolysaccharidosis (MPS VI, Maroteaux-Lamy syndrome). The TxGNN model predicts it may be effective for ptosis-strabismus-ectopic pupils syndrome, but there are 0 clinical trials and 0 publications supporting this prediction. The prediction is model-only, and no plausible biological rationale was identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Mucopolysaccharidosis (the Singapore licence text for the approved indication is blank) |
| Predicted New Indication | Ptosis-strabismus-ectopic pupils syndrome |
| TxGNN Prediction Score | 97.89% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, galsulfase is a recombinant form of N-acetylgalactosamine-4-sulfatase (ARSB). This enzyme breaks down dermatan sulfate in lysosomes, and replacing it is the established treatment for MPS VI.
Ptosis-strabismus-ectopic pupils syndrome is a rare congenital ocular and neuro-developmental condition. It has no known accumulation of glycosaminoglycans (GAGs), so there is no clear reason why replacing ARSB would help. The high TxGNN score most likely reflects closeness to other eye-related conditions in the knowledge graph, not a biological rationale.
The same conclusion applies to the other top-ranked predictions (ranks 2-9). These are congenital eyelid, ocular-motility and neuro-ophthalmic conditions, and none has a known link to GAG storage or to galsulfase. They are:
- Camptodactyly, myopia and fibrosis of the medial rectus muscle
- Congenital Horner syndrome
- Ptosis-vocal cord paralysis syndrome
- Ptosis-upper ocular movement limitation-absence of lacrimal punctum syndrome
- Jaw-winking syndrome
- Congenital entropion
- Epiblepharon
- Congenital ectropion
The only prediction with a pathway-level connection is Scheie syndrome (rank 10, score 94.79%, evidence level L4). It is the attenuated form of MPS I, caused by IDUA deficiency, and it involves dermatan sulfate storage. ARSB acts further down the same degradation pathway, which gives some indirect plausibility. However, the defective enzyme in Scheie syndrome is upstream, so galsulfase would not correct the primary defect, and laronidase is already the approved therapy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
The only literature retrieved relates to the lower-ranked Scheie syndrome prediction (rank 10). None was retrieved for the top-ranked prediction.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22210671 | 2011 | Review | Rheumatology (Oxford) | Overview of MPS therapy; enzyme replacement is available for MPS I (including Scheie syndrome), MPS II and other types. It does not test galsulfase in Scheie syndrome. |
| 21211680 | 2010 | Review | La Revue de médecine interne | Review of enzyme replacement therapy across lysosomal storage diseases. It does not test galsulfase in Scheie syndrome. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16831P | Naglazyme Concentrate for Solution for Infusion 5 mg/5 mL | Infusion, solution concentrate | Not stated in the data compiled for this report |
Safety Considerations
No drug interactions were found in the data compiled for this report, and no drug-disease contraindications were recorded in the knowledge graph.
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction rests only on the model score. There are no clinical trials or publications, and no plausible mechanism links ARSB enzyme replacement to this congenital eye syndrome. The same applies to ranks 2-9. The only biologically related candidate, Scheie syndrome, is already treated by its own enzyme replacement (laronidase), and ARSB would not correct its primary defect.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA (currently a blocking gap for safety screening)
- Detailed mechanism of action data
- Any mechanistic or preclinical evidence linking GAG or dermatan sulfate accumulation to the predicted ocular syndromes
- Route and formulation compatibility assessment (galsulfase is available only as an intravenous infusion, which may not suit ocular conditions)
- If the research question is pursued, a focused review of Scheie syndrome and other MPS subtypes sharing dermatan sulfate storage
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.